| abstract |
The precursors of the proton pump inhibitor medicaments of the pyridylmethylsulfinylbenzimidazole type have a hydrolysable sulfinyl or arylsulfonyl group attached to the benzimidazole nitrogen, or include a group that forms a Mannich base with the benzimidazole nitrogen. The precursors of the invention are hydrolyzed under physiological conditions to provide proton pump inhibitors with a measurable half-life in hours, and are capable of providing sustained plasma concentrations of proton pump inhibitor medications for longer than medications. currently used The generation of proton pump inhibitor drugs from the precursors of the invention under physiological conditions allows a more effective treatment of various diseases and conditions caused by gastric acid secretion. |